Status and phase
Conditions
Treatments
About
Phase II:To explore the optimal effective dose of SHR7280 tablets in subjects with menorrhagia with uterine fibroids as a phase III treatment dose.
Phase III:To evaluate the efficacy of the selected dose of SHR7280 compared with placebo in reducing menstrual bleeding in subjects with menorrhagic uterine fibroids in phase II studies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
357 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Zhenyi Zhu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal